Pharmaceuticals News

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related...

MELBOURNE, Australia and OXFORD, United Kingdom, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for...

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related...

Samþykki FDA gerir Alvotech kleift að framleiða virka lyfjaefnið í Humira hliðstæðuna fyrir Bandaríkjamarkað í báðum framleiðslueiningum verksmiðjunnar í ReykjavíkStaðfestir þetta enn frekar að...

COPENHAGEN, Denmark, October 5, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase...

KØBENHAVN, Danmark, 5. oktober 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 1. september 2026, hvorunder selskabet vil...

MILAN, Oct. 04, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its...

SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow,...

Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration...

VB Health launches a seven-part supplement quality standard covering research, dosing, sourcing, U.S. manufacturing, testing and transparency.